Excretion of berberine and its metabolites in oral administration in rats.

Berberine (BBR) has been confirmed to show extensive bioactivities for the treatments of diabetes and hypercholesterolemia in clinic. However, there are few pharmacokinetic studies to elucidate the excretions of BBR and its metabolites. Our research studied the excretions of BBR and its metabolites in rats after oral administration (200 mg/kg). Metabolites in bile, urine, and feces were detected by liquid chromatography coupled to ion trap time-of-flight mass spectrometry; meanwhile, a validated liquid chromatography coupled with tandem mass spectrometry method was developed for their quantifications. Sixteen metabolites, including 10 Phase I and six Phase II metabolites were identified and clarified after dosing in vivo. Total recovered rate of BBR was 22.83% (19.07% of prototype and 3.76% of its metabolites) with 9.2 × 10(-6) % in bile (24 h), 0.0939% in urine (48 h), and 22.74% in feces (48 h), respectively. 83% of BBR was excreted as thalifendine (M1) from bile, whereas thalifendine (M1) and berberrubine (M2) were the major metabolites occupying 78% of urine excretion. Most of BBR and its metabolites were found in feces containing 84% of prototype. In summary, we provided excretion profiles of BBR and its metabolites after oral administration in rats in vivo.

[1]  W. Jia,et al.  Effects and mechanisms of berberine in diabetes treatment , 2012 .

[2]  Xingguo Cheng,et al.  CYP2D plays a major role in berberine metabolism in liver of mice and humans , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[3]  Wei-Jia Kong,et al.  Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes , 2011, Journal of Translational Medicine.

[4]  Ning Kang,et al.  Metabolites of protoberberine alkaloids in human urine following oral administration of Coptidis Rhizoma decoction. , 2010, Planta medica.

[5]  F. Qiu,et al.  Short Communication Isolation and Identification of Urinary Metabolites of Berberine in Rats and Humans , 2008 .

[6]  Bo Tan,et al.  Simultaneous quantification of three alkaloids of Coptidis Rhizoma in rat urine by high‐performance liquid chromatography: application to pharmacokinetic study , 2007, Biopharmaceutics & drug disposition.

[7]  N. Nakamura,et al.  Pharmacokinetics of Berberine and Its Main Metabolites in Conventional and Pseudo Germ-Free Rats Determined by Liquid Chromatography/Ion Trap Mass Spectrometry , 2006, Drug Metabolism and Disposition.

[8]  Zejun Li,et al.  Radioiodination, biodistribution and pharmacokinetics of berberine in mice , 2005 .

[9]  Satoru Inaba,et al.  Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins , 2004, Nature Medicine.

[10]  T. Tsai,et al.  Hepatobiliary excretion of berberine. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[11]  Da-yuan Zhu,et al.  Identification of three sulfate-conjugated metabolites of berberine chloride in healthy volunteers' urine after oral administration. , 2002, Acta pharmacologica Sinica.

[12]  C. Yu,et al.  Determination and Preliminary Studies of Metabolism of Berberine in Human Urine After Oral Administration , 2000 .

[13]  N. Iizuka,et al.  Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines. , 2000, Cancer letters.

[14]  C. M. Chen,et al.  Determination of berberine in plasma, urine and bile by high-performance liquid chromatography. , 1995, Journal of chromatography. B, Biomedical applications.

[15]  Yong-Xiao Wang,et al.  Effects of Berberine on Delayed Afterdepolarizations in Ventricular Muscles In Vitro and In Vivo , 1994, Journal of cardiovascular pharmacology.

[16]  K. Chang,et al.  Berberine-induced morphologic differentiation and down-regulation of c-Ki-ras2 protooncogene expression in human teratocarcinoma cells. , 1990, Cancer letters.